Laird Norton Wetherby Trust Company’s Evoke Pharma EVOK Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-76	Closed	-$5K	–	144
2022 Q1	$5K	Buy	+76	New	+$6.06K	﹤0.01%	192

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Laird Norton Wetherby Trust Company's EVOK Position: Q2 2022 in Review

Laird Norton Wetherby Trust Company sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 76 shares — an estimated $5K sold.

Laird Norton Wetherby Trust Company first reported a position in EVOK in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

Laird Norton Wetherby Trust Company reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
Laird Norton Wetherby Trust Company sold 76 Evoke Pharma shares in Q2 2022, an estimated $5K.
Laird Norton Wetherby Trust Company first reported a position in Evoke Pharma in Q1 2022 and held it in 1 quarter.
Laird Norton Wetherby Trust Company's Evoke Pharma position peaked at $5K in Q1 2022.
12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2022, filed 3 Aug 2022.